Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 4/2015

Open Access 01-07-2015

A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart

Authors: Satsuki Fukushima, Shigeru Miyagawa, Yoshiki Sakai, Yoshiki Sawa

Published in: Heart Failure Reviews | Issue 4/2015

Login to get access

Abstract

Cardiac failure is a major cause of mortality and morbidity worldwide, since the standard treatment for cardiac failure in the clinical practice is chiefly to focus on removal of insults against the heart or minimisation of additional factors to exacerbate cardiac failure, but not on regeneration of the damaged cardiac tissue. A synthetic prostacyclin agonist, ONO-1301, has been developed as a long-acting drug for acute and chronic pathologies related to regional ischaemia, inflammation and/or interstitial fibrosis by pre-clinical studies. In addition, poly-lactic co-glycolic acid-polymerised form of ONO-1301, ONO-1301SR, was generated to achieve a further sustained release of this drug into the targeted region. This unique reagent has been shown to act on fibroblasts, vascular smooth muscle cells and endothelial cells in the tissue via the prostaglandin IP receptor to exert paracrinal release of multiple protective factors, such as hepatocyte growth factor, vascular endothelial growth factor or stromal cell-derived factor-1, into the adjacent damaged tissue, which is salvaged and/or regenerated as a result. Our laboratory developed a new surgical approach to treat acute and chronic cardiac failure using a variety of animal models, in which ONO-1301SR is directly placed over the cardiac surface to maximise the therapeutic effects and minimise the systemic complications. This review summarises basic and pre-clinical information of ONO-1301 and ONO-1301SR as a new reagent to enhance tissue salvage and/or regeneration, with a particular focus on the therapeutic effects on acute and chronic cardiac failure and underlying mechanisms, to explore a potential in launching the clinical study.
Literature
1.
Felker GM, Shaw LK, O’Connor CM (2002) A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39:210–218PubMedCrossRef
2.
3.
Jiang F, Yang J, Zhang Y et al (2014) Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol 11:413–426PubMedCrossRef
4.
Lang CC, Struthers AD (2013) Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol 10:125–134PubMedCrossRef
5.
Koitabashi N, Kass DA. (2012) Reverse remodeling in heart failure[mdash]mechanisms and therapeutic opportunities. Nat Rev Cardiol 9:147–157
6.
Zucker IH, Xiao L, Haack KK (2014) The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 126:695–706CrossRef
7.
Cohn JN (2014) Heart failure in 2013: continue what we are doing to treat HF, but do it better. Nat Rev Cardiol 11:69–70PubMedCrossRef
8.
9.
Menasche P (2011) Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 50:258–265PubMedCrossRef
10.
Fukushima S, Sawa Y, Suzuki K (2013) Choice of cell-delivery route for successful cell transplantation therapy for the heart. Future Cardiol 9:215–227PubMedCrossRef
11.
Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ (2014) Cell therapy for cardiac repair; lessons from clinical trials. Nat Rev Cardiol 11:232–246PubMedCrossRef
12.
Sanganalmath SK, Bolli R (2013) Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113:810–834PubMedCentralPubMedCrossRef
13.
Tous E, Purcell B, Ifkovits J, Burdick J (2011) Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res 4:528–542PubMedCrossRef
14.
Chawengsub Y, Gauthier KM, Campbell WB (2009) Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 297:H495–H507PubMedCentralPubMedCrossRef
15.
16.
Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y (2013) A novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J Pharmacol Sci 123:392–401PubMedCrossRef
17.
Takahashi HK, Iwagaki H, Tamura R et al (2003) Unique regulation profile of prostaglandin E1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 307:1188–1195PubMedCrossRef
18.
Takahashi HK, Iwagaki H, Tamura R et al (2005) Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes. Eur J Pharmacol 512:223–230PubMedCrossRef
19.
Takahashi HK, Iwagaki H, Mori S, Yoshino T, Tanaka N, Nishibori M (2005) Prostaglandins E1 and E2 inhibit lipopolysaccharide-induced interleukin-18 production in monocytes. Eur J Pharmacol 517:252–256PubMedCrossRef
20.
Imanishi Y, Miyagawa S, Fukushima S et al (2013) Sustained-release delivery of prostacyclin analogue enhances bone marrow-cell recruitment and yields functional benefits for acute myocardial infarction in mice. PLoS One 8:e69302PubMedCentralPubMedCrossRef
21.
Ishimaru K, Miyagawa S, Fukushima S et al (2013) Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart. J Thorac Cardiovasc Surg 146:1516–1525PubMedCrossRef
22.
Kubota Y, Miyagawa S, Fukushima S et al (2014) Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. J Thorac Cardiovasc Surg 147:1081–1087PubMedCrossRef
23.
Shirasaka T, Miyagawa S, Fukushima S et al (2013) A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing–induced model of canine heart failure. J Thorac Cardiovasc Surg 146:413–421PubMedCrossRef
24.
Imawaka H, Sugiyama Y (1998) Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J Pharmacol Exp Ther 284:949–957PubMed
25.
Uchida T, Hazekawa M, Morisaki T, Yoshida M, Sakai Y (2013) Effect of antioxidants on the stability of ONO-1301, a novel long-acting prostacyclin agonist, loaded in PLGA microspheres. J Microencapsul 30:245–256PubMedCrossRef
26.
Tsai MK, Hsieh CC, Kuo HF et al (2014) Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate. J Invest Med 62:332–339
27.
Nakamura K, Sata M, Iwata H et al (2007) A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond) 112:607–616CrossRef
28.
Xiao CY, Yuhki KI, Hara A et al (2004) Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109:2462–2468PubMedCrossRef
29.
Tanaka M, Sakai A, Uchida S et al (2004) Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34:940–948PubMedCrossRef
30.
Sasaoka R, Terai H, Toyoda H, Imai Y, Sugama R, Takaoka K (2004) A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun 318:704–709PubMedCrossRef
31.
Pagkalos J, Leonidou A, As-Sultany M, Heliotis M, Mantalaris A, Tsiridis E (2012) Prostaglandin E(2) receptors as potential bone anabolic targets—selective EP4 receptor agonists. Curr Mol Pharmacol 5:174–181PubMedCrossRef
32.
Ninomiya T, Hosoya A, Hiraga T et al (2011) Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol 650:396–402PubMedCrossRef
33.
Namikawa T, Terai H, Hoshino M et al (2007) Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine (Phila Pa 1976) 32:2294–2299CrossRef
34.
Nakagawa K, Imai Y, Ohta Y, Takaoka K (2007) Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 41:543–548PubMedCrossRef
35.
Marui A, Hirose K, Maruyama T et al (2006) Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats. J Thorac Cardiovasc Surg 131:587–593PubMedCrossRef
36.
Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, Maruyama T (2006) Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39:453–459PubMedCrossRef
37.
Hayashi K, Fotovati A, Ali SA, Oda K, Oida H, Naito M (2005) Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis. J Bone Joint Surg Br 87:1150–1156PubMedCrossRef
38.
Hagino H, Kuraoka M, Kameyama Y, Okano T, Teshima R (2005) Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone 36:444–453PubMedCrossRef
39.
Chang F, Mishima H, Ishii T et al (2007) Stimulation of EP4 receptor enhanced bone consolidation during distraction osteogenesis. J Orthop Res 25:221–229PubMedCrossRef
40.
Sekiguchi M, Konno SI, Kikuchi SI (2006) Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine 31:869–872PubMedCrossRef
41.
Kasai K, Sato SI, Suzuki K (2001) A novel prostaglandin E receptor subtype agonist, ONO-4819, attenuates acute experimental liver injury in rats. Hepatol Res 21:252–260PubMedCrossRef
42.
Honma Y, Arai I, Hashimoto Y et al (2005) Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 518:56–62PubMedCrossRef
43.
Nakagawa N, Yuhki KI, Kawabe JI et al (2012) The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 82:158–171PubMedCrossRef
44.
Nakase H, Fujiyama Y, Oshitani N et al (2010) Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis 16:731–733PubMedCrossRef
45.
Hishikari K, Suzuki JI, Ogawa M et al (2009) Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 81:123–132PubMedCentralPubMedCrossRef
46.
Ogawa M, Suzuki JI, Kosuge H, Takayama K, Nagai R, Isobe M (2009) The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 87:1645–1653PubMedCrossRef
47.
Ngoc PB, Suzuki J, Ogawa M et al (2011) The anti-inflammatory mechanism of prostaglandin e2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol 57:365–372PubMedCrossRef
48.
O’Farrell FM, Attwell D (2014) A role for pericytes in coronary no-reflow. Nat Rev Cardiol 11:427–432PubMedCrossRef
49.
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ (2014) Cardioprotection and pharmacological therapies in acute myocardial infarction: challenges in the current era. World J Cardiol 6:100–106PubMedCentralPubMedCrossRef
50.
51.
Camici PG, d’Amati G, Rimoldi O. (2015) Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 12:48-62
52.
Giblett JP, West NEJ, Hoole SP (2014) Cardioprotection for percutaneous coronary intervention-Reperfusion quality as well as quantity. Int J Cardiol 177:786–793PubMedCrossRef
53.
Sivaraman V, Yellon DM (2014) Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther 19:83–96PubMedCrossRef
54.
Moukarbel GV, Ayoub CM, Abchee AB (2004) Pharmacological therapy for myocardial reperfusion injury. Curr Opin Pharmacol 4:147–153PubMedCrossRef
55.
Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW (2006) Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27:2400–2405PubMedCrossRef
56.
Wang X, Wei M, Kuukasjärvi P et al (2009) The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J 43:72–79PubMedCrossRef
57.
Wong GTC, Huang Z, Ji S, Irwin MG (2010) Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth 24:790–796PubMedCrossRef
58.
Lønborg J, Vejlstrup N, Kelbæk H et al (2012) Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33:1491–1499PubMedCrossRef
59.
Kitakaze M, Asakura M, Kim J et al (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483–1493PubMedCrossRef
60.
Najjar SS, Rao SV, Melloni C et al (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305:1863–1872PubMedCentralPubMedCrossRef
61.
Diaz R, Goyal A, Mehta SR et al (2007) Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 298:2399–2405PubMedCrossRef
62.
Garcia C, Julier K, Bestmann L et al (2005) Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 94:159–165PubMedCrossRef
63.
Yusuf S, Macmahon S, Collins R, Peto R (1998) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 331:1088–1092CrossRef
64.
Kim JS, Kim J, Choi D et al (2010) Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. The STATIN STEMI trial. JACC Cardiovasc Interv 3:332–339PubMedCrossRef
65.
66.
Piot C, Croisille P, Staat P et al (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473–481PubMedCrossRef
67.
Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA (2012) Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 59:9–15PubMedCrossRef
68.
Fukushima S, Coppen SR, Varela-Carver A et al (2006) Enhanced efficiency of superoxide dismutase-induced cardioprotection by retrograde intracoronary administration. Cardiovasc Res 69:459–465PubMedCrossRef
69.
Fukushima S, Coppen SR, Varela-Carver A et al (2006) A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 114:I251–I256PubMedCrossRef
70.
Hirata Y, Shimabukuro M, Uematsu E et al (2012) A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol 674:352–358PubMedCrossRef
71.
Iwata H, Nakamura K, Sumi M et al (2009) Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci 85:255–261PubMedCrossRef
72.
Hirata Y, Soeki T, Akaike M, Sakai Y, Igarashi T, Sata M (2009) Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters. Biomed Pharmacother 63:781–786PubMedCrossRef
73.
Suzuki JI, Ogawa M, Sakai Y, Hirata Y, Isobe M, Nagai R (2012) A prostacycline analog prevents chronic myocardial remodeling in murine cardiac allografts. Int Heart J 53:64–67PubMedCrossRef
74.
Hirata Y, Kurobe H, Uematsu E et al (2013) Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol 699:81–87PubMedCrossRef
75.
Kainuma S, Miyagawa S, Fukushima S et al (2015) Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. Mol Ther 23:374–386PubMedCrossRef
76.
Mann DL, Kubo SH, Sabbah HN et al (2012) Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg 143:1036–1042PubMedCentralPubMedCrossRef
77.
Fukushima S, Campbell NG, Coppen SR et al (2011) Quantitative assessment of initial retention of bone marrow mononuclear cells injected into the coronary arteries. J Heart Lung Transplant 30:227–233PubMedCrossRef
78.
Fukushima S, Varela-Carver A, Coppen SR et al (2007) Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation 115:2254–2261PubMedCrossRef
79.
Miyagawa S, Saito A, Sakaguchi T et al (2010) Impaired myocardium regeneration with skeletal cell sheets—a preclinical trial for tissue-engineered regeneration therapy. Transplantation 90:364–372PubMedCrossRef
80.
Shudo Y, Miyagawa S, Fukushima S et al (2011) Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model. J Thorac Cardiovasc Surg 142:1188–1196PubMedCrossRef
81.
Zamanian RT, Kudelko KT, Sung YK, de Jesus Perez V, Liu J, Spiekerkoetter E (2014) Current clinical management of pulmonary arterial hypertension. Circ Res 115:131–147PubMedCrossRef
82.
Ruan CH, Dixon RA, Willerson JT, Ruan KH (2010) Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J 37:391–399PubMedCentralPubMed
83.
Kataoka M, Nagaya N, Satoh T et al (2005) A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 172:1575–1580PubMedCrossRef
84.
Antoniu SA (2006) Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 15:327–330PubMedCrossRef
85.
Obata H, Sakai Y, Ohnishi S et al (2008) Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med 177:195–201PubMedCrossRef
86.
Nakamura A, Nagaya N, Obata H et al (2013) Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circ J 77:2127–2133PubMedCrossRef
87.
Murakami S, Nagaya N, Itoh T et al (2006) Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 290:L59–L65PubMedCrossRef
88.
Hayashi M, Koya T, Kawakami H et al (2010) A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice. Clin Exp Allergy 40:317–326PubMedCrossRef
89.
Kimura Y, Koya T, Kagamu H et al (2013) A single injection of a sustained-release prostacyclin analog (ONO-1301MS) suppresses airway inflammation and remodeling in a chronic house dust mite-induced asthma model. Eur J Pharmacol 721:80–85PubMedCrossRef
90.
Hayashi K, Nagamatsu T, Oka T, Suzuki Y (1997) Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol 73:73–82PubMedCrossRef
91.
Yamasaki H, Maeshima Y, Nasu T et al (2011) Intermittent administration of a sustained-release prostacyclin analog ONO-1301 ameliorates renal alterations in a rat type 1 diabetes model. Prostaglandins Leukot Essent Fatty Acids 84:99–107PubMedCrossRef
92.
Nasu T, Kinomura M, Tanabe K et al (2012) Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol 302:F1616–F1629PubMedCrossRef
93.
Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T (2012) The effect of treatment with a sustained-release prostacyclin analogue (ONO-1301-loaded PLGA microsphere) on short-term memory impairment in rats with transient global cerebral ischemia. J Microencapsul 29:211–218PubMedCrossRef
94.
Hazekawa M, Sakai Y, Yoshida M, Haraguchi T, Uchida T (2012) Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion. J Pharm Pharmacol 64:353–359PubMedCrossRef
95.
Xu Q, Nakayama M, Suzuki Y et al (2012) Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression. Am J Physiol Gastrointest Liver Physiol 302:G420–G429PubMedCrossRef
96.
Xu Q, Sakai K, Suzuki Y, Tambo C, Sakai Y, Matsumoto K (2013) Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist. Biomed Res 34:241–250PubMedCrossRef
97.
Niina Y, Ito T, Oono T et al (2014) A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology 14:201–210PubMedCrossRef
98.
Lederle FA, Freischlag JA, Kyriakides TC et al (2012) Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med 367:1988–1997PubMedCrossRef
99.
Malina M, Brunkwall J, Ivancev K, Jönsson J, Malina J, Lindblad B (2000) Endovascular healing is inadequate for fixation of dacron stent-grafts in human aortoiliac vessels. Eur J Vasc Endovasc Surg 19:5–11PubMedCrossRef
100.
Watanabe Y, Miyagawa S, Fukushima S et al (2014) Development of a prostacyclin-agonist–eluting aortic stent graft enhancing biological attachment to the aortic wall. J Thorac Cardiovasc Surg 148(2325–34):e1PubMed
101.
Agarwal S, Tuzcu EM, Krishnaswamy A et al (2015) Transcatheter aortic valve replacement: current perspectives and future implications. Heart 101:169–177PubMedCrossRef
Metadata
Title
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart
Authors
Satsuki Fukushima
Shigeru Miyagawa
Yoshiki Sakai
Yoshiki Sawa
Publication date
01-07-2015
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 4/2015
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-015-9477-8

Other articles of this Issue 4/2015

Heart Failure Reviews 4/2015 Go to the issue

OriginalPaper

BAG3: a new player in the heart failure paradigm

OriginalPaper

Effects of apelin on the cardiovascular system

OriginalPaper

High salt intake as a multifaceted cardiovascular disease: new support from cellular and molecular evidence

Letter to the Editor

T-wave/QRS complex amplitude correlations with myocardial edema in patients with takotsubo syndrome

OriginalPaper

Left ventricular assist devices: a kidney’s perspective

OriginalPaper

Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations